Introduction
Chronic myelogenous leukemia (CML) is a condition that has evolved from a fatal disease to a manageable chronic condition, with many patients now living long, healthy lives. Thanks to significant advances in treatment, survival rates for CML patients have dramatically improved, with 91% and 84% survival rates at five and ten years, respectively.
At our multidisciplinary hematology clinic in Tel Aviv, Israel, we specialize in providing expert, patient-centered care for individuals diagnosed with CML. We combine advanced treatment protocols, personalized care plans, and a compassionate team approach to help patients achieve the best possible outcomes.
About CML
CML is caused by changes in the hematopoietic stem cells of the bone marrow, specifically by the Philadelphia chromosome, found in 95% of cases. Without effective treatment, the disease progresses through three phases: chronic, accelerated, and blast crisis. Early diagnosis and treatment at a specialized hematology clinic in Israel are key to long-term survival and quality of life.
Treatment History and Evolution
Historically, CML treatments included arsenic, radiation, and chemotherapy. The introduction of tyrosine kinase inhibitors (TKIs) revolutionized treatment. Today, five TKIs are used to treat CML:
– Imatinib (Glivec)
– Dasatinib (Sprycel)
– Nilotinib (Tasigna)
– Bosutinib (Bosulif)
– Ponatinib (Iclusig)
Treatment in Our Hematology Clinic in Tel Aviv
Our experienced hematology team in Tel Aviv, Israel, offers a personalized approach to CML treatment. We follow international protocols while tailoring therapy to each patient’s condition and lifestyle.
Personalized Treatment Based on Disease Stage
In the chronic phase, first-line treatment includes one of three TKIs: Imatinib, Nilotinib, or Dasatinib. Treatment decisions are made in collaboration between the patient and our hematology specialists in Tel Aviv.
For patients in the accelerated or blast phase, we may recommend higher doses of TKIs or allogeneic bone marrow transplantation, performed at leading medical centers in Israel, including our clinic.
Personalized Treatment Based on Risk Level
We assess the patient’s risk using validated indices like the Sokal and Hasford scores. This helps us provide tailored treatment and improve long-term outcomes.
Monitoring Treatment Response
Monitoring the patient’s molecular and cytogenetic response is essential. An early molecular response within three months of treatment is a strong predictor of long-term success. Our clinic provides regular testing and adjusts treatment accordingly.
Managing TKI Resistance
In cases of TKI resistance, our Tel Aviv hematology clinic performs mutation testing and may adjust treatment by switching to a second- or third-generation TKI. In some cases, allogeneic stem cell transplantation is considered.
Future Directions in CML Treatment in Israel
We are closely involved in clinical research and offer our patients access to the latest trials and experimental treatments. Our goal is to provide not only treatment but also hope for a cure.
Discontinuation of TKI Therapy
In selected patients who achieve a complete molecular response, TKI treatment may be safely discontinued under close medical supervision. Our clinic follows international protocols to manage this process.
Why Choose Our Hematology Clinic in Tel Aviv?
– Located in central Israel, easily accessible to patients across the country
– Multidisciplinary team of hematology experts
– Advanced diagnostic and treatment technologies
– Personalized care plans for CML patients
– Access to innovative therapies and clinical trials in Israel
Contact Us for Expert CML Treatment in Tel Aviv
If you or someone you care about has been diagnosed with chronic myelogenous leukemia (CML), contact our hematology clinic in Tel Aviv today. We are committed to providing expert care, advanced treatments, and compassionate support.
Schedule a consultation and receive world-class hematology care in the heart of Israel.
